ETF Battles: Which Pharmaceutical ETF Should You Buy? Watch PPH Vs. PJP Vs. XPH
Image Source: Unsplash
In this episode of ETF Battles, I referee an audience-requested triple-header contest between a trio of pharmaceutical ETFs from Invesco (PJP), SPDR State Street Global Advisors (XPH), and VanEck (PPH).
David Dierking with TheStreet.com and Tom Psarofagis with Bloomberg Intelligence judge the ETF match-up, sharing their investing research insights. Each ETF is judged against the other in key categories like cost, exposure strategy, performance, and a mystery category. Find out who wins the battle.
00:15:21
Disclosure: ETF Battles is sponsored by: Direxion Daily Leveraged & Inverse ETFs.
Disclosure: None
Disclaimer: Ron DeLegge has analyzed and graded more than $125 million with ...
more
How did you like this article? Let us know so we can better customize your reading experience.
Comments
Leave a comment to automatically be entered into
our contest to win a free Echo Show.
